Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 109pembrolizumab 93Pemetrexed 83Cisplatin 67Specimen Handling 41durvalumab 36Paclitaxel 36Nivolumab 33Docetaxel 33atezolizumab 30Magnetic Resonance Spectroscopy 30osimertinib 29Radiotherapy 21Gemcitabine 21Etoposide 21130-nm albumin-bound paclitaxel 19Cetuximab 17amivantamab 14Radiosurgery 13Radiation 12Platinum 12Bevacizumab 12lazertinib 11cemiplimab 11Taxes 11Immunoglobulin G 11Topotecan 10Ipilimumab 10Drug Therapy 10Disulfides 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glutamate Carboxypeptidase II × Thoracic × 30 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡